Innoviva Inc
INVA
Company Profile
Business description
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Contact
1350 Old Bayshore Highway
Suite 400
BurlingameCA94010
USAT: +1 650 238-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
159
Stocks News & Analysis
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,628.30 | 34.80 | -0.40% |
| CAC 40 | 7,806.76 | 1.11 | -0.01% |
| DAX 40 | 22,817.72 | 21.84 | -0.10% |
| Dow JONES (US) | 46,046.83 | 25.40 | 0.06% |
| FTSE 100 | 10,082.44 | 18.94 | 0.19% |
| HKSE | 25,277.32 | 223.26 | -0.88% |
| NASDAQ | 21,973.90 | 116.79 | -0.53% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 12,989.99 | 61.62 | -0.47% |
| S&P 500 | 6,591.50 | 14.99 | -0.23% |
| S&P/ASX 200 | 8,428.40 | 43.90 | -0.52% |
| SSE Composite Index | 3,957.05 | 49.50 | -1.24% |